EyePoint DSMC gives positive recommendation for Phase 3 DURAVYU wet AMD trials; no protocol changes

EyePoint, Inc.

DSMC completed second scheduled review of Phase 3 LUGANO and LUCIA trials; no modifications recommended.
All patients reached Week 8; ~25% received second planned DURAVYU dose at Week 32.
Masked safety data shows no safety signals, consistent with prior DURAVYU trials.
Topline 56-week data for LUGANO on track for mid-2026; LUCIA data to follow closely.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.